Advertisement

Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation

Published:November 04, 2019DOI:https://doi.org/10.1016/j.amjcard.2019.10.014
      The development of aortic valve stenosis is strongly associated with older adults. Patients who undergo transcatheter aortic valve implantation (TAVI) for severe aortic stenosis frequently have heart failure (HF). We investigated the predictors of mortality after TAVI according to the presence of HF, and specifically HF with preserved ejection fraction (HFpEF) versus HF with reduced ejection fraction (HFrEF). Patients were identified from the Nationwide Inpatient Sample registry from January 2011 to September 2015 using the ICD-9 codes. Patients with HF who underwent TAVI were classified according to whether they were diagnosed with HFrEF or HFpEF. The principal outcome of interest was in-hospital mortality. Multivariable analysis was used to adjust for potential baseline confounders. Among 11,609 patients undergoing TAVI, 6,368 (54.9%) had baseline HF, including 4,290 (67.4%) with HFpEF and 2,078 (32.6%) with HFrEF. In TAVI patients with HF, in-hospital mortality was also not significantly different in those with HFrEF compared with HFpEF (3.66% vs 3.17%, respectively; adjusted odds ratio 1.14, 95% confidence interval 0.84 to 1.53; p = 0.38). Polyvalvular heart disease was an additional independent predictor of in-hospital mortality in HFrEF, whereas age, liver disease, and the absence of depression and anemia were additional independent predictors of mortality in HFpEF. In conclusion, baseline HF in patients undergoing TAVI is prevalent and is more commonly due to HFpEF than HFrEF. Mortality is similar in those with HFrEF and HFpEF. Knowledge of the specific predictors of mortality after TAVI in HF patients may be useful for patient selection and prognostic guidance.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mack MJ
        • Leon MB
        • Thourani VH
        • Makkar R
        • Kodali SK
        • Russo M
        • Kapadia SR
        • Malaisrie SC
        • Cohen DJ
        • Pibarot P
        Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients.
        N Engl J Med. 2019; 18: 1695-1705
        • Popma JJ
        • Deeb GM
        • Yakubov SJ
        • Mumtaz M
        • Gada H
        • O'Hair D
        • Bajwa T
        • Heiser JC
        • Merhi W
        • Kleiman NS
        Transcatheter aortic-valve replacement with a self-expandin valve in low-risk patients.
        N Engl J Med. 2019; 18: 1706-1715
        • Lam CSP
        • Gamble GD
        • Ling LH
        • Sim D
        • Leong KTG
        • Yeo PSD
        • Ong HY
        • Jaufeerally F
        • Ng TP
        • Cameron VA
        • Poppe K
        • Lund M
        • Devlin G
        • Troughton R
        • Richards AM
        • Doughty RN
        Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study.
        Eur Heart J. 2018; 39: 1770-1780
        • Goyal P
        • Almarzooq ZI
        • Horn EM
        • Karas MG
        • Sobol I
        • Swaminathan RV
        • Feldman DN
        • Minutello RM
        • Singh HS
        • Bergman GW
        • Wong SC
        • Kim LK
        Characteristics of hospitalizations for heart failure with preserved ejection fraction.
        Am J Med. 2016; 129 (635.e15-26)
        • Khera R
        • Angraal S
        • Couch T
        • Welsh JW
        • Nallamothu BK
        • Girotra S
        • Chan PS
        • Krumholz HM
        Adherence to methodological standards in research using the national inpatient sample.
        JAMA. 2017; 318: 2011-2018
        • Anderson RP
        First publications from the society of thoracic surgeons national database.
        Ann Thorac Surg. 1994; 57: 6-7
        • Nashef SA
        • Roques F
        • Michel P
        • Gauducheau E
        • Lemeshow S
        • Salamon R
        European system for cardiac operative risk evaluation (EuroSCORE).
        Eur J Cardiothorac Surg. 1999; 16: 9-13
        • Roques F
        • Michel P
        • Goldstone AR
        • Nashef SA
        The logistic EuroSCORE.
        Eur Heart J. 2003; 24: 881-882
        • Perlman GY
        • Loncar S
        • Pollak A
        • Gilon D
        • Alcalai R
        • Planer D
        • Lotan C
        • Danenberg HD
        Post-procedural hypertension following transcatheter aortic valve implantation: incidence and clinical significance.
        JACC Cardiovasc Interv. 2013; 6: 472-478
        • Webb JG
        • Altwegg L
        • Boone RH
        • Cheung A
        • Ye J
        • Lichtenstein S
        • Lee M
        • Masson JB
        • Thompson C
        • Moss R
        • Carere R
        • Munt B
        • Nietlispach F
        • Humphries K
        Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes.
        Circulation. 2009; 119: 3009-3016
        • Thomas M
        • Schymik G
        • Walther T
        • Himbert D
        • Lefevre T
        • Treede H
        • Eggebrecht H
        • Rubino P
        • Michev I
        • Lange R
        • Anderson WN
        • Wendler O
        Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve.
        Circulation. 2010; 122: 62-69
        • Lefèvre T
        • Kappetein AP
        • Wolner E
        • Nataf P
        • Thomas M
        • Schächinger V
        • De Bruyne B
        • Eltchaninoff H
        • Thielmann M
        • Himbert D
        • Romano M
        • Serruys P
        • Wimmer-Greinecker G
        • Group PEI
        One year follow-up of the multi-centre European PARTNER transcatheter heart valve study.
        Eur Heart J. 2011; 32: 148-157
        • Williamson JD
        • Supiano MA
        • Applegate WB
        • Berlowitz DR
        • Campbell RC
        • Chertow GM
        • Fine LJ
        • Haley WE
        • Hawfield AT
        • Ix JH
        • Kitzman DW
        • Kostis JB
        • Krousel-Wood MA
        • Launer LJ
        • Oparil S
        • Rodriguez CJ
        • Roumie CL
        • Shorr RI
        • Sink KM
        • Wadley VG
        • Whelton PK
        • Whittle J
        • Woolard NF
        • Wright Jr., JT
        • Pajewski NM
        Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged >/=75 years: a randomized clinical trial.
        JAMA. 2016; 315: 2673-2682
        • James PA
        • Oparil S
        • Carter BL
        • Cushman WC
        • Dennison-Himmelfarb C
        • Handler J
        • Lackland DT
        • LeFevre ML
        • MacKenzie TD
        • Ogedegbe O
        • Smith Jr., SC
        • Svetkey LP
        • Taler SJ
        • Townsend RR
        • Wright Jr., JT
        • Narva AS
        • Ortiz E
        2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).
        JAMA. 2014; 311: 507-520
        • Wright Jr., JT
        • Williamson JD
        • Whelton PK
        • Snyder JK
        • Sink KM
        • Rocco MV
        • Reboussin DM
        • Rahman M
        • Oparil S
        • Lewis CE
        • Kimmel PL
        • Johnson KC
        • Goff Jr., DC
        • Fine LJ
        • Cutler JA
        • Cushman WC
        • Cheung AK
        • Ambrosius WT
        A randomized trial of intensive versus standard blood-pressure control.
        N Engl J Med. 2015; 373: 2103-2116
        • Anker SD
        • Negassa A
        • Coats AJ
        • Afzal R
        • Poole-Wilson PA
        • Cohn JN
        • Yusuf S
        Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.
        Lancet. 2003; 361: 1077-1083
        • Iversen PO
        • Woldbaek PR
        • Tonnessen T
        • Christensen G
        Decreased hematopoiesis in bone marrow of mice with congestive heart failure.
        Am J Physiol Regul Integr Comp Physiol. 2002; 282: R166-R172
        • Gupta T
        • Goel K
        • Kolte D
        • Khera S
        • Villablanca PA
        • Aronow WS
        • Bortnick AE
        • Slovut DP
        • Taub CC
        • Kizer JR
        • Pyo RT
        • Abbott JD
        • Fonarow GC
        • Rihal CS
        • Garcia MJ
        • Bhatt DL
        Association of chronic kidney disease with in-hospital outcomes of transcatheter aortic valve replacement.
        JACC Cardiovasc Interv. 2017; 10: 2050-2060
        • Beohar N
        • Doshi D
        • Thourani V
        • Jensen H
        • Kodali S
        • Zhang F
        • Zhang Y
        • Davidson C
        • McCarthy P
        • Mack M
        • Kapadia S
        • Leon M
        • Kirtane A
        Association of transcatheter aortic valve replacement with 30-day renal function and 1-year outcomes among patients presenting with compromised baseline renal function: experience from the PARTNER 1 trial and registry.
        JAMA Cardiol. 2017; 2: 742-749
        • Humphries KH
        • Toggweiler S
        • Rodes-Cabau J
        • Nombela-Franco L
        • Dumont E
        • Wood DA
        • Willson AB
        • Binder RK
        • Freeman M
        • Lee MK
        • Gao M
        • Izadnegahdar M
        • Ye J
        • Cheung A
        • Webb JG
        Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis.
        J Am Coll Cardiol. 2012; 60: 882-886
        • Nombela-Franco L
        • Ribeiro HB
        • Urena M
        • Allende R
        • Amat-Santos I
        • DeLarochelliere R
        • Dumont E
        • Doyle D
        • DeLarochelliere H
        • Laflamme J
        • Laflamme L
        • Garcia E
        • Macaya C
        • Jimenez-Quevedo P
        • Cote M
        • Bergeron S
        • Beaudoin J
        • Pibarot P
        • Rodes-Cabau J
        Significant mitral regurgitation left untreated at the time of aortic valve replacement: a comprehensive review of a frequent entity in the transcatheter aortic valve replacement era.
        J Am Coll Cardiol. 2014; 63: 2643-2658
        • Kiramijyan S
        • Magalhaes MA
        • Koifman E
        • Didier R
        • Escarcega RO
        • Minha S
        • Baker NC
        • Negi SI
        • Torguson R
        • Gai J
        • Okubagzi P
        • Asch FM
        • Gaglia Jr., MA
        • Ben-Dor I
        • Satler LF
        • Pichard AD
        • Waksman R
        Impact of baseline mitral regurgitation on short- and long-term outcomes following transcatheter aortic valve replacement.
        Am Heart J. 2016; 178: 19-27
        • D'Onofrio A
        • Gasparetto V
        • Napodano M
        • Bianco R
        • Tarantini G
        • Renier V
        • Isabella G
        • Gerosa G
        Impact of preoperative mitral valveregurgitation on outcomes after transcatheter aortic valve implantation.
        Eur J Cardiothorac Surg. 2012; 41 (discussion 1276-1277): 1271-1276
        • Hutter A
        • Bleiziffer S
        • Richter V
        • Opitz A
        • Hettich I
        • Mazzitelli D
        • Ruge H
        • Lange R
        Transcatheter aortic valve implantation in patients with concomitant mitral and tricuspid regurgitation.
        Ann Thorac Surg. 2013; 95: 77-84
        • Mowakeaa S
        • Dwivedi A
        • Grossman JR
        • Parikh G
        • Curillova Z
        • Aragam KG
        • Elmariah S
        • Kinlay S
        • Aragam J
        Prognosis of patients with secondary mitral regurgitation and reduced ejection fraction.
        Open heart. 2018; 5e000745
        • Sung S-H
        • Wang T-J
        • Cheng H-M
        • Yu W-C
        • Guo C-Y
        • Chiang C-E
        • Chen C-H
        Clinical characteristics and outcomes in the very elderly patients hospitalized for acute heart failure: importance of pharmacologic guideline adherence.
        Sci Rep. 2018; 8: 14270
        • Yoshihisa A
        • Sato Y
        • Yokokawa T
        • Sato T
        • Suzuki S
        • Oikawa M
        • Kobayashi A
        • Yamaki T
        • Kunii H
        • Nakazato K
        • Saitoh SI
        • Takeishi Y
        Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction.
        ESC Heart Fail. 2018; 5: 262-270
        • Caughey MC
        • Avery CL
        • Ni H
        • Solomon SD
        • Matsushita K
        • Wruck LM
        • Rosamond WD
        • Loehr LR
        Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance).
        Am J Cardiol. 2014; 114: 1850-1854
        • Young JB
        • Abraham WT
        • Albert NM
        • Gattis Stough W
        • Gheorghiade M
        • Greenberg BH
        • O'Connor CM
        • She L
        • Sun JL
        • Yancy CW
        • Fonarow GC
        Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry).
        Am J Cardiol. 2008; 101: 223-230
        • Latado AL
        • Passos LC
        • Darze ES
        • Lopes AA
        Comparison of the effect of anemia on in-hospital mortality in patients with versus without preserved left ventricular ejection fraction.
        Am J Cardiol. 2006; 98: 1631-1634